Ipsen S.A. publishes its 2024 consolidated financial statements

February 21, 2025 09:42 ET | Source: Ipsen Pharma Ipsen Pharma

Ipsen S.A. - 2024 Consolidated Financial Statements

Attachment

Ipsen_Consolidated financial statements 2024_EN

Attachments

Ipsen_Consolidated financial statements 2024_EN

Ipsen_Consolidated financial statements 2024_EN...

Recommended Reading

February 19, 2026 04:26 ET | Source: Ipsen Pharma

Ipsen S.A. publishes its 2025 Consolidated Financial Statements

Ipsen S.A. publishes its 2025 Consolidated Financial Statements Attachment Ipsen_Consolidated financial statements 2025_GB ...
Read More
February 12, 2026 01:00 ET | Source: Ipsen Pharma

Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance

FY 2025 sales growth of 10.9% at CER1, or 8.1% as reported, driven by growth of the three therapeutic areas of Oncology (4.1%1), Rare Disease (102.5%1) and Neuroscience (9.7%1); Somatuline® sales...
Read More